<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1905245320
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Calquence
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Acalabrutinib
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        21385.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AstraZeneca AB" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AstraZeneca AB
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AstraZeneca UK Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01X
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>What CALQUENCE is</strong></p><p dir="ltr">CALQUENCE is a medicine used to treat cancer. CALQUENCE tablets contain acalabrutinib, an active substance belongs to the Bruton tyrosine kinase (BTK) inhibitor class of anti-cancer medicines.</p><p dir="ltr"><strong>What CALQUENCE is used for </strong></p><p dir="ltr">CALQUENCE is used for the treatment of adults with:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mantle cell lymphoma (MCL), who have received at least one prior treatment for their cancer</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>How CALQUENCE works</strong></p><p dir="ltr">CALQUENCE blocks BTK and can reduce the number of cancer cells and slow the progression of the disease.</p><p dir="ltr">CALQUENCE will only be prescribed to you by a doctor with experience in the use of medicines for cancer.</p><p dir="ltr">If you have any questions about how CALQUENCE works or why this medicine has been prescribed for you, ask your doctor.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Warnings and precautions</strong></p><p dir="ltr">Do not take CALQUENCE&reg; if you are allergic to acalabrutinib or any of the other</p><p dir="ltr">ingredients of CALQUENCE&reg;<strong> </strong>Talk to your doctor before taking CALQUENCE if you:</p><ul dir="ltr"><li>have recently undergone surgery or are about to undergo surgery. Your doctor may stop treatment with CALQUENCE before a medical, surgical or dental procedure.</li><li>have a bleeding disorder.</li><li>have an infection.</li><li>have liver problems.</li><li>have or had a liver infection (hepatitis B), so that your doctor can look out for signs of reactivation of this infection, such as fever, chills, weakness, confusion, vomiting and jaundice (yellowing of the skin or eyeballs).</li><li>have or had heart rhythm problems.</li><li>are pregnant or planning to become pregnant.</li><li>are breast-feeding or planning to breast-feed.</li></ul><p dir="ltr">If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before taking CALQUENCE.</p><p dir="ltr"><strong>When you take CALQUENCE, you can have some serious side effects. </strong></p><p dir="ltr"><strong>If you have any of the following, call or see your doctor right away. Your doctor may tell you to decrease your dose, temporarily stop, or completely stop taking CALQUENCE if you have certain side effects.</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding problems (haemorrhage). Signs and symptoms may include black stools or stools with blood, pink or brown urine, nosebleeds, bruising, unexpected bleeding, vomiting or coughing up blood, dizziness, weakness, confusion, changes in your speech, bruising or red or purple skin marks or headache lasting a long time.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections (bacterial, viral, or fungal). Signs and symptoms may include fever or chills, or flu-like symptoms.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of blood cell counts. These may be a decreased number of red blood cell counts, decreased number of low white blood cell counts, or decreased number of cells that help blood clot (platelets). Your doctor will check your blood cell counts as needed during treatment with CALQUENCE.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; second primary cancers. Other cancers may happen during treatment with CALQUENCE, including cancers of the skin.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart rhythm problems (atrial fibrillation or atrial flutter). Signs and symptoms may include fast or abnormal heartbeat, dizziness, feeling faint, chest discomfort, or shortness of breath.</p><p dir="ltr"><strong>Children and Adolescents</strong></p><p dir="ltr">The safety and efficacy of CALQUENCE has not been established in children or adolescents. Do not give this medicine to children or adolescents aged less than 18 years.</p><p dir="ltr"><strong>Pregnancy</strong></p><p dir="ltr">Talk to your doctor before taking CALQUENCE if you are pregnant, think you may be pregnant or are planning on having a baby. This is because CALQUENCE may harm your unborn baby. If you are pregnant, you should not take CALQUENCE. You should not get pregnant while you are taking this medicine.</p><p dir="ltr"><strong>Breast-feeding</strong></p><p dir="ltr">Before taking CALQUENCE, tell your doctor if you are breast-feeding. It is not known if CALQUENCE passes into your breast milk. Do not breast-feed during treatment with CALQUENCE and for 2 days after your final dose of CALQUENCE.</p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr">CALQUENCE is unlikely to affect the ability to drive and use machines. However, if you feel dizzy, weak or tired while taking CALQUENCE, take special care when driving or using machines.</p><p dir="ltr"><strong>Taking other medicines</strong></p><p dir="ltr">Tell your doctor and pharmacist if you are taking or have recently taken any other medicines, including medicines not prescribed, herbal medicines, and supplements.</p><p dir="ltr"><strong>CALQUENCE may make you bleed more easily.</strong> This means you should tell your doctor if you take other medicines that increase your risk of bleeding. This includes:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acetyl salicylic acid and non-steroidal anti-inflammatories (NSAIDs)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to prevent blood clots, such as antiplatelet therapy or blood thinners</p><p dir="ltr">Some medicines can affect the levels of CALQUENCE in your body. Also, CALQUENCE can affect the way some other medicines work. Tell your doctor if you are taking any of the following:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antibiotics used to treat bacterial infections (e.g. clarithromycin)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat fungal infections (e.g. posaconazole, ketoconazole, itraconazole, voriconazole)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat HIV infections (e.g. indinavir)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat hepatitis C (e.g. telaprevir)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampin, an antibiotic used to treat bacterial infections</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to prevent seizures or to treat epilepsy (e.g. carbamazepine, phenytoin)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s wort, a herbal medicine, used for instance to treat depression</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methotrexate, a medicine used to treat immune disorders</p><p dir="ltr">Tell your doctor or pharmacist if you take any of these or any other medicines. The medicines listed here may not be the only ones that could interact with CALQUENCE.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Your doctor has prescribed CALQUENCE&nbsp;<strong>film-coated tablets</strong>&nbsp;for you. Please note CALQUENCE is also available as a 100 mg <strong>capsule</strong> and should not be interchanged with CALQUENCE film-coated tablets.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Always take CALQUENCE exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is one 100 mg tablet twice a day. Doses should be taken about 12 hours apart.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablet whole with water at approximately the same time each day.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take CALQUENCE with or without food.</p><p dir="ltr">&middot;&nbsp; &nbsp;&nbsp;&nbsp;You can check when you last took a tablet of CALQUENCE by looking on the blister. There is a sun (for the morning) and a moon (for the evening). This will tell you whether you have taken the dose.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not chew, crush, dissolve, or divide the tablets.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you take more Calquence than you should</strong></p><p dir="ltr">If you may have taken more CALQUENCE than you should, see a doctor or go to the nearest hospital straight away.</p><p dir="ltr"><strong>If you forget to take a dose</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss a dose by less than 3 hours, take the missed dose right away. Take the next dose at your usual time.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss a dose by more than 3 hours, skip the missed dose. Take the next dose at your usual time.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take any extra tablets of CALQUENCE to make up for a missed dose.</p><p dir="ltr"><strong>If you stop taking CALQUENCE</strong></p><p dir="ltr">Do not stop taking CALQUENCE unless your doctor tells you. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, CALQUENCE can have side effects, although not everybody gets them. These side effects may occur with certain frequencies, which are defined as follows:</p><p dir="ltr"><strong>Very common (affects more than 1 in 10 people) side effects that may occur are:</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection, signs include fever, chills, or flu-like symptoms</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bruising</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle and bone pain</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; new cancers</p><p dir="ltr"><strong>The following side effects are very commonly shown in blood tests:</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of white blood cells</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of red blood cells</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of cells that help blood clot (platelets)</p><p dir="ltr"><strong>Common (affects up to 1 in 10 people) side effects that may occur are:</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nose bleeds</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-melanoma skin cancer</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness or lack of energy</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heart rate, missed heart beats, weak or uneven pulse, dizziness, feeling faint, chest pain, shortness of breath (symptoms of atrial fibrillation)</p><p dir="ltr"><strong>Uncommon (affects up to 1 in 100 people) side effect that may occur is:</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; condition called tumour lysis syndrome (TLS), when there are unusual levels of chemicals in the blood caused by the fast breakdown of cancer cells, has happened during treatment of cancer and sometimes even without treatment. Signs of TLS are changes in kidney function, abnormal heartbeat, or seizures.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the reach and sight of children.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in original package.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use CALQUENCE after the expiry date (EXP) which is stated on the white plastic bottle, blister foil, and carton. The expiry date refers to the last day of that month.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 25&deg;C.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>What CALQUENCE contains</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is acalabrutinib.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are</p><p dir="ltr"><u>Tablet Core</u>: mannitol, microcrystalline cellulose, low-substituted&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;hydroxypropyl cellulose, sodium stearyl fumarate</p><p dir="ltr"><u>Tablet Coating</u>: hypromellose 2910, copovidone, titanium dioxide, macrogol 3350, medium-chain triglycerides, iron oxide yellow (E172), iron oxide red (E172), purified water</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                CALQUENCE is an orange, 7.5 x 13 mm, oval, biconvex tablet, debossed with ‘ACA 100’ on one side and plain on the reverse.

Calquence is supplied in aluminium blisters containing either 8 or 10 film-coated tablets. On each blister there are sun/moon symbols to help you to take your dose at the right time — the sun for the morning dose and the moon for the evening dose. Both the sun and the moon blisters contain the same medicine. Each carton contains either 56 or 60 film-coated tablets

Not all packs sizes will be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Marketing Authorisation Holder</strong></p><p dir="ltr">AstraZeneca UK Ltd</p><p dir="ltr">Charter Way,&nbsp;Cheshire</p><p dir="ltr">SK102NA,&nbsp;Macclesfield</p><p dir="ltr">United Kingdom</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Manufacturer</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">AstraZeneca AB</p><p dir="ltr">G&auml;rtunav&auml;gen</p><p dir="ltr">SE-151 85 S&ouml;dert&auml;lje</p><p dir="ltr">Sweden</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو كالكوينس</strong></p><p dir="RTL">إن كالكوينس عبارة عن دواء يُستخدم لعلاج السرطان. تحتوي أقراص كالكوينس على أكالابروتينيب، وهي مادة فعالة تنتمي إلى فئة مثبط كيناز تيروسين بروتون (BTK) بالأدوية المضادة للسرطان.</p><p dir="RTL"><strong>دواعي استعمال كالكوينس</strong></p><p dir="RTL">يُستخدم كالكوينس لعلاج البالغين الذين يعانون من:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لمفومة الخلايا القشرية (MCL) الذين تلقوا علاجًا سابقًا واحدًا على الأقل للسرطان لديهم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابيضاض الدم الليمفاوي المزمن (CLL)/اللمفومة اللمفاوية الصغيرة (SLL).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يعمل كالكوينس</strong></p><p dir="RTL">يثبط كالكوينس إنزيم BTK ويمكن أن يقلل من عدد الخلايا السرطانية ويبطئ من تقدّم المرض.</p><p dir="RTL">إن الطبيب ذا الخبرة في استخدام أدوية السرطان هو الوحيد الذي يمكنه أن يصف لك عقار كالكوينس.</p><p dir="RTL">إذا كانت لديك أي أسئلة حول كيفية عمل عقار كالكوينس أو سبب وصفه لك، فاسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">لا تتناول كالكوينس اذا كنت تعاني من حساسية مفرطة من أكالابروتينيب أو أي من المكونات الأخرى لهذا الدواء.</p><p dir="RTL">تحدّث إلى طبيبك قبل تناول كالكوينس إذا كنت:</p><ul><li dir="RTL">خضعت مؤخرًا لجراحة أو على وشك الخضوع لجراحة. قد يوقف طبيبك العلاج بكالكوينس قبل أي إجراء طبي، أو جراحي أو إجراء خاص بالأسنان.</li><li dir="RTL">تعاني من اضطراب نزفي.</li><li dir="RTL">مصاب بعدوى.</li><li dir="RTL">تعاني من مشكلات في الكبد.</li><li dir="RTL">تعاني أو عانيت سابقًا من عدوى في الكبد (التهاب الكبد ب)، حيث سيبحث طبيبك عن أي علامات تدل على إعادة نشاط هذه العدوى، مثل الحمى أو القشعريرة أو الضعف أو الارتباك أو القيء أو اليرقان (اصفرار الجلد أو مقلة العين).</li><li dir="RTL">تعاني أو عانَيتَ من مشكلات في نظم القلب.</li><li dir="RTL">سيدة حامل أو تخططين للحمل.</li><li dir="RTL">ترضعين رضاعة طبيعية أو تخططين للإرضاع.</li></ul><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو إذا لم تكن متأكدًا)، فتحدّث إلى طبيبك، أو الصيدلي أو الممرضة قبل تناول كالكوينس.</p><p dir="RTL"><strong>عندما تتناول كالكوينس، يمكن أن تعاني من بعض الآثار الجانبية الخطيرة.</strong></p><p dir="RTL"><strong>إذا كنت تعاني من أيٍّ مما يلي، فاتصل بطبيبك أو توجه لزيارته فورًا. قد يطلب منك طبيبك تقليل جرعتك، أو التوقف مؤقتًا، أو التوقف تمامًا عن تناول عقار كالكوينس إذا ظهرت عليك آثار جانبية معيّنة.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات النزف (النزيف الدموي). قد تشمل العلامات والأعراض البراز الأسود أو البراز المصحوب بالدم، أو البول الوردي أو البني، أو نزيف الأنف، أو التكدّم، أو النزيف غير المتوقع، أو القيء أو السعال المصحوب بالدم، أو الدوخة، أو الضعف، أو الارتباك، أو التغيّرات في الكلام، أو الصداع الذي يستمر لفترة طويلة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات عدوى (بكتيرية، أو فيروسية، أو فطرية). قد تشمل العلامات والأعراض الحمى أو القشعريرة أو أعراض تشبه أعراض الإنفلونزا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد خلايا الدم. قد يكون ذلك انخفاض في أعداد خلايا الدم الحمراء، أو انخفاض أعداد خلايا الدم البيضاء، أو انخفاض أعداد الخلايا التي تساعد الدم على التجلط (الصفائح الدموية). سيفحص طبيبك أعداد خلايا الدم لديك حسب الحاجة أثناء العلاج بكالكوينس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السرطانات الأولية الثانية. قد تحدث سرطانات أخرى أثناء العلاج بعقار كالكوينس، بما في ذلك سرطانات الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في نظم القلب (الرجفان الأذيني أو الرفرفة الأذينية). قد تشمل العلامات والأعراض ضربات قلب سريعة أو غير طبيعية، أو دوخة، أو شعور بالإغماء، أو عدم راحة في الصدر، أو ضيق في التنفس.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لم تثبت سلامة وفعالية كالكوينس لدى الأطفال أو المراهقين. لا تُعطِ هذا الدواء للأطفال أو المراهقين الذين تقل أعمارهم عن 18 عامًا.</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">تحدثي إلى طبيبك قبل تناول كالكوينس إذا كنتِ حاملًا، أو تعتقدين أنك قد تكوني حاملًا، أو تخططين للحمل. ويرجع السبب في ذلك إلى أن كالكوينس قد يضر جنينك. إذا كنتِ حاملًا، ينبغي ألا تتناولي كالكوينس. ينبغي عليك عدم الحمل أثناء تناول هذا الدواء.</p><p dir="RTL"><strong>الإرضاع الطبيعي</strong></p><p dir="RTL">قبل تناول كالكوينس، أخبري طبيبكِ إذا كنتِ ترضعين رضاعة طبيعية. ليس معروفًا ما إذا كان عقار كالكوينس ينتقل إلى حليب ثديك أم لا. لا ترضعي طفلكِ رضاعة طبيعية أثناء العلاج بعقار كالكوينس ولمدة يومين على الأقل بعد جرعتك الأخيرة من عقار كالكوينس.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المحتمل أن يؤثر كالكوينس على قدرتك على القيادة واستخدام الآلات. ومع ذلك، إذا شعرت بالدوار، أو الضعف أو التعب أثناء تناول كالكوينس، فتوخى الحرص بشكل خاص عند القيادة أو استخدام الآلات.</p><p dir="RTL"><strong>تناول أدوية أخرى</strong></p><p dir="RTL">أخبر طبيبك والصيدلي إذا كنت تتناول أو قد تناولت مؤخرًا أي أدوية أخرى، بما في ذلك الأدوية غير الموصوفة، والأدوية العشبية، والمكملات الغذائية.</p><p dir="RTL"><strong>قد يجعلك كالكوينكس تنزف بسهولة أكبر. </strong>وهذا يعني أنه ينبغي عليك إخبار طبيبك إذا كنت تتناول أدوية أخرى تزيد من خطر إصابتك بالنزيف. وهذا يشتمل على:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض الأسيتيل ساليسيليك ومضادات الالتهاب غير الستيرويدية (NSAIDs)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة للوقاية من الجلطات الدموية، مثل العلاج المضاد للصفائح الدموية أو مرققات الدم</p><p dir="RTL">يمكن أن تؤثر بعض الأدوية على مستويات كالكوينس في جسمك. كذلك، يمكن لعقار كالكوينكس أن يؤثر على طريقة عمل الأدوية الأخرى. أخبر طبيبك إذا كنت تتناول أيًا مما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية المستخدمة لعلاج حالات العدوى البكتيرية (مثل كلاريثرومايسين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج حالات العدوى الفطرية (مثل بوساكونازول، كيتوكونازول، إيتراكونازول، فوريكونازول)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج حالات عدوى فيروس نقص المناعة البشرية (مثل، إندينافير)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج التهاب الكبد سي (مثل، تيلابريفير)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبين وهو مضاد حيوي يُستخدم لعلاج حالات العدوى البكتيرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة للوقاية من النوبات التشنجية أو لعلاج الصرع (مثل، كاربامازيبين، وفينيتوين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سان جونز، وهي دواء عشبي يستخدم على سبيل المثال لعلاج الاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتريكسات وهو دواء يُستخدم لعلاج اضطرابات المناعة</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أيًا من هذه الأدوية أو أي أدوية أخرى. قد لا تكون الأدوية المذكورة هنا الأدوية الوحيدة التي يمكن أن تتفاعل مع كالكوينس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لقد وصف لك طبيبك <strong>أقراص كالكوينس المغلفة</strong>. يُرجى ملاحظة أن كالكوينس متوفر أيضًا في شكل <strong>كبسولة</strong> 100 ملغ وينبغي عدم استبداله بأقراص كالكوينس المغلفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احرص دائمًا على تناول عقار كالكوينكس تمامًا كما أخبرك طبيبك. استشر طبيبك أو الصيدلي لديك إذا لم تكن متأكدًا من طريقة تناوله.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة قرصًا واحدًا 100 ملغ مرتين يوميًا. ينبغي تناول الجرعات بفارق 12 ساعة&nbsp;تقريبًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع القرص كاملًا مع الماء في نفس الوقت تقريبًا كل يوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول عقار كالكوينس مع الطعام أو بدونه.</p><p dir="RTL">&middot;&nbsp; يمكنك التحقق من آخر مرة تناولت فيها قرص كالكوينس بالنظر على الشريط. يوجد شكل شمس (للصباح) وقمر (للمساء). سيخبرك هذا ما إذا كنت قد تناولت الجرعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تمضغ الأقراص، أو تسحقها، أو تذيبها أو تقسمها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت جرعة زائدة من كالكوينكس من تلك الموصوفة لك</strong></p><p dir="RTL">إذا كنت قد تناولت جرعة من كالكوينس أكثر من تلك الموصوفة لك، فاستشر طبيبًا أو اذهب إلى أقرب مستشفى على الفور.</p><p dir="RTL"><strong>إذا نسيت تناول إحدى الجرعات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا مضي أقل من 3 ساعات على نسيان تناول إحدى الجرعات، فتناول الجرعة الفائتة على الفور. وتناول الجرعة التالية في الوقت المعتاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا فاتتك جرعة لأكثر من 3 ساعات، فتخطى الجرعة الفائتة. وتناول الجرعة التالية في الوقت&nbsp;المعتاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول أقراصًا إضافية من كالكوينكس لتعويض جرعة فائتة.</p><p dir="RTL"><strong>إذا توقفت عن تناول كالكوينس</strong></p><p dir="RTL">لا تتوقف عن تناول كالكوينس إلا إذا أخبرك طبيبك بذلك. إذا كان لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن سائر الأدوية، يمكن أن يُسبب عقار كالكوينكس آثارًا جانبية، ولكن لا يتأثر بها جميع الأشخاص. قد تحدث هذه الآثار الجانبية بدرجات شيوع معيّنة، والتي يتم تعريفها على النحو التالي:</p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدًا (تصيب أكثر من شخص واحد من بين كل 10 أشخاص) التي قد تحدث&nbsp;وهي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى، تشمل العلامات الحمى، أو القشعريرة، أو أعراض تشبه الإنفلونزا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التكدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات والعظام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطانات جديدة</p><p dir="RTL"><strong>الآثار الجانبية التالية شائعة جدًا في اختبارات الدم:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد خلايا الدم البيضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد خلايا الدم الحمراء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد الخلايا التي تساعد الدم على التجلط (الصفائح الدموية)</p><p dir="RTL"><strong>الآثار الجانبية الشائعة (قد تصيب حتى شخص واحد من بين 10 أشخاص) التي قد تحدث وهي:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات نزيف الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجلد غير الميلاني</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف أو نقص في الطاقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة معدل ضربات القلب، نبضات القلب غير منتظمة، ضعف أو عدم انتظام النبض، دوخة، الشعور بالإغماء، ألم في الصدر، ضيق في التنفس (أعراض الرجفان الأذيني)</p><p dir="RTL"><strong>الأثر الجانبي غير الشائع (قد يصيب حتى شخص واحد من بين 100 شخص) الذي قد يحدث وهو:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد حدثت حالة تسمى متلازمة انحلال الورم (TLS)، عندما تكون هناك مستويات غير معتادة من المواد الكيميائية في الدم بسبب التحلل السريع للخلايا السرطانية، وذلك أثناء علاج السرطان وأحيانًا حتى دون علاج. تتمثل علامات متلازمة انحلال الورم في تغيّرات في وظائف الكلى، أو ضربات قلب غير طبيعية، أو نوبات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدواء بعيدًا عن متناول ومرأى الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في العبوة الأصلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم عقار كالكوينكس بعد تاريخ انتهاء الصلاحية (EXP) المُدوّن على الزجاجة البلاستيكية البيضاء، وشريط الأقراص والعبوة الكرتونية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في درجة حرارة أقل من 25 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي عدم التخلص من الأدوية عبر مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات كالكوينس</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي أكالابروتينيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وتتمثل المكونات الأخرى في</p><p dir="RTL"><u>نواة القرص</u>: مانيتول، سليلوز بلوري دقيق، هيدروكسي بروبيل السليلوز منخفض الاستبدال، فومارات ستيريل الصوديوم</p><p dir="RTL"><u>الطبقة الخارجية للقرص: </u>هيبروميلوز 2910، كوبوفيدون، ثاني أكسيد التيتانيوم، ماكروغول 3350، ثلاثي الجلسريدات متوسط السلسلة، أكسيد الحديد الأصفر (E172)، أكسيد الحديد الأحمر (E172)، والماء المنقى</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل عقار كالكوينس ومحتويات العبوة</strong></p><p dir="RTL">كالكوينس عبارة عن قرص برتقالي اللون، بحجم 7.5 &times; 13 مم، بيضاوي الشكل، محدب الوجهين، منقوش عليه &quot;ACA 100&quot; على جانب واحد ومستوٍ على الجانب الآخر.</p><p dir="RTL">يتم توفير كالكوينس في شرائط من الألومنيوم تحتوي إما على 8 أو 10 أقراص مغلفة. توجد على كل شريط رموز للشمس/القمر لمساعدتك على تناول جرعتك في الوقت المناسب - الشمس لجرعة الصباح والقمر لجرعة المساء. وتحتوي كل من شرائط الشمس والقمر على نفس الدواء. تحتوي كل علبة كرتونية على 56 أو 60 قرصًا مغلفًا</p><p dir="RTL">لن يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق</strong></p><p dir="RTL">AstraZeneca UK Ltd</p><p dir="RTL">Charter Way, Cheshire</p><p dir="RTL">SK102NA, Macclesfield</p><p dir="RTL">المملكة المتحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جهة التصنيع</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">AstraZeneca AB</p><p dir="RTL">G&auml;rtunav&auml;gen</p><p dir="RTL">SE-151 85 S&ouml;dert&auml;lje</p><p dir="RTL">السويد</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أكتوبر 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Calquence 100 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 100 mg of acalabrutinib (as acalabrutinib maleate).

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet). 

Orange, 7.5 x 13 mm, oval, biconvex tablet, debossed with ‘ACA 100’ on one side and plain on the reverse.  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Calquence is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>(This indication is approved under accelerated approval based on overall response rate, Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials)</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">Calquence is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Treatment with this medicinal product should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Posology</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Calquence as Monotherapy</u></p><p dir="ltr">For patients with MCL, CLL, or SLL, the recommended dosage of CALQUENCE is 100 mg taken orally approximately every 12 hours until disease progression or unacceptable toxicity.</p><p dir="ltr"><u>Calquence in Combination with Obinutuzumab</u></p><p dir="ltr">For patients with previously untreated CLL or SLL, the recommended dosage of CALQUENCE is 100&nbsp;mg taken orally approximately every 12 hours until disease progression or unacceptable toxicity. Start CALQUENCE at Cycle 1 (each cycle is 28 days). Start Obinutuzumab at Cycle 2 for a total of 6 cycles and refer to the Obinutuzumab prescribing information for recommended dosing. Administer Calquence prior to Obinutuzumab when given on the same day.</p><p dir="ltr">Advise patients to swallow tablet whole with water. Advise patients not to chew, crush, dissolve, or cut the tablets. Calquence may be taken with or without food. If a dose of CALQUENCE is missed by more than 3 hours, it should be skipped and the next dose should be taken at its regularly scheduled time. Extra tablets of Calquence should not be taken to make up for a missed dose.</p><p dir="ltr"><u>Dose adjustments</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em>Adverse reactions</em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">Recommended dose modifications of Calquence for Grade &ge; 3 adverse reactions are provided in Table 1.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table 1. Recommended dose adjustments for adverse reactions*</strong></p><p dir="ltr"><strong><sup>&nbsp;</sup></strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction occurrence</strong></p></td><td style="vertical-align:top"><p><strong>Dose modification</strong></p><p>(Starting dose = 100mg approximately every 12 hours)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Grade 3 or greater non-hematologic toxicities,</p><p>Grade 3 thrombocytopenia with bleeding,</p><p>Grade 4 thrombocytopenia or</p><p>Grade 4 neutropenia lasting longer than 7 days</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>First and second</p></td><td style="vertical-align:top"><p>Interrupt Calquence</p><p>Once toxicity has resolved to Grade 1 or baseline, Calquence may be resumed at 100mg approximately every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>Third</p></td><td style="vertical-align:top"><p>Interrupt Calquence</p><p>Once toxicity has resolved to Grade 1 or baseline, Calquence may be resumed at a reduced frequency of 100mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Fourth</p></td><td style="vertical-align:top"><p>Discontinue Calquence</p></td></tr></tbody></table><p dir="ltr">*Adverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Refer to the Obinutuzumab prescribing information for management of Obinutuzumab toxicities.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Interactions</em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">Recommendations regarding use of Calquence with CYP3A inhibitors or inducers are provided in Table 2 (see section 4.5).</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table 2. Use with CYP3A inhibitors or inducers </strong></p><p dir="ltr"><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:98%"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Co-administered medicinal product </strong></p></td><td><p><strong>Recommended Calquence use</strong></p></td></tr><tr><td rowspan="2"><p><strong>Induction</strong></p></td><td><p>Strong CYP3A inhibitor</p></td><td><p>Avoid co-administration.</p><p>If these inhibitors will be used short-term (such as anti‑infectives for up to seven days), interrupt Calquence.</p><p>After discontinuation of strong CYP3A inhibitor for at least 24 hours, resume previous dosage of Calquence.</p></td></tr><tr><td><p>Moderate CYP3A inhibitor</p></td><td><p>Reduce the CALQUENCE 100 mg every 12 hours dosage to 100 mg once daily.</p></td></tr><tr><td><p><strong>Induction</strong></p></td><td><p>Strong CYP3A inducer</p></td><td><p>Avoid co-administration.</p><p>&nbsp;If co-administration is unavoidable, increase Calquence dosage to 200 mg approximately every 12 hours</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">Acalabrutinib tablets can be co-administered with gastric acid reducing agents (proton pump inhibitors, H2-receptor antagonists, antacids), unlike acalabrutinib capsules which show impaired uptake when given with acid reducing agents (see section 4.5).</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Missed dose<em> </em></u></p><p dir="ltr"><br />If a patient misses a dose of Calquence by more than 3 hours, the patient should be instructed to take the next dose at its regularly scheduled time. Double dose of Calquence should not be taken to make up for a missed dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Special populations</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em>Elderly</em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">No dose adjustment is required for elderly patients (aged &ge; 65 years) (see section 5.2).</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em>Renal impairment</em></p><p dir="ltr">&nbsp;</p><p dir="ltr">There were no clinically significant differences in the pharmacokinetics of acalabrutinib and its active metabolite, ACP-5862, based on age (32 to 90 years), sex, race (Caucasian, African American), body weight (40 to 149 kg), or mild to moderate renal impairment (eGFR &ge;&nbsp;30&nbsp;mL/min/1.73m<sup>2</sup> and eGFR &lt;&nbsp;89&nbsp;mL/min/1.73m<sup>2</sup>, as estimated by MDRD (modification of diet in renal disease equation)). The effect of severe renal impairment (eGFR &lt;&nbsp;29&nbsp;mL/min/1.73m<sup>2</sup>, MDRD) or renal impairment requiring dialysis on the pharmacokinetics of acalabrutinib is unknown.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em>Hepatic impairment</em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">The AUC of acalabrutinib increased 1.9-fold in subjects with mild hepatic impairment (Child-Pugh class A), 1.5-fold in subjects with moderate hepatic impairment (Child-Pugh class B) and 5.3-fold in subjects with severe hepatic impairment (Child-Pugh class C) compared to subjects with normal liver function. No clinically relevant PK difference in ACP-5862 was observed in subjects with severe hepatic impairment (Child-Pugh Class C) compared to subjects with normal liver function. No clinically relevant PK differences in acalabrutinib and ACP-5862 were observed in patients with mild or moderate hepatic impairment (total bilirubin less and equal to upper limit of normal [ULN] and AST greater than ULN, or total bilirubin greater than ULN and any AST) relative to patients with normal hepatic function (total bilirubin and AST within ULN).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Severe cardiac disease</em></p><p dir="ltr"><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p dir="ltr">Patients with severe cardiovascular disease were excluded from Calquence clinical studies.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em>Paediatric population</em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">The safety and efficacy of Calquence in children and adolescents aged 0 to 18 years have not been established. No data are available.<br />&nbsp;</p><p dir="ltr"><u>Method of administration </u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Calquence is for oral use. The tablets should be swallowed whole with water at approximately the same time each day, with or without food (see section 4.5). The tablets should not be chewed, crushed, dissolved or divided.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Haemorrhage</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Fatal and serious hemorrhagic events have occurred in patients with hematologic malignancies treated with Calquence. Major hemorrhage (serious or Grade 3 or higher bleeding or any central nervous system bleeding) occurred in 3.0% of patients, with fatal hemorrhage occurring in 0.1% of 1029 patients exposed to Calquence in clinical trials. Bleeding events of any grade, excluding bruising and petechiae, occurred in 22% of patients</p><p dir="ltr">Use of antithrombotic agents concomitantly with Calquence may further increase the risk of hemorrhage. In clinical trials, major hemorrhage occurred in 2.7% of patients taking Calquence without antithrombotic agents and 3.6% of patients taking Calquence with antithrombotic agents. Consider the risks and benefits of antithrombotic agents when co-administered with Calquence. Monitor patients for signs of bleeding.</p><p dir="ltr">Consider the benefit-risk of withholding Calquence for 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Infections</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Fatal and serious infections, including opportunistic infections, have occurred in patients with hematologic malignancies treated with Calquence.</p><p dir="ltr">Serious or Grade 3 or higher infections (bacterial, viral, or fungal) occurred in 19% of 1029 patients exposed to Calquence in clinical trials, most often due to respiratory tract infections (11% of all patients, including pneumonia in 6%), These infections predominantly occurred in the absence of Grade 3 or 4 neutropenia, with neutropenic infection reported in 1.9% of all patients. Opportunistic infections in recipients of Calquence have included, but are not limited to, hepatitis B virus reactivation, fungal pneumonia, <em>Pneumocystis jirovecii</em> pneumonia, Epstein-Barr virus reactivation, cytomegalovirus, and progressive multifocal leukoencephalopathy (PML). Consider prophylaxis in patients who are at increased risk for opportunistic infections. Monitor patients for signs and symptoms of infection and treat promptly.</p><p dir="ltr">(see section 4.8).</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><u>Cytopenias</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Grade 3 or 4 cytopenias, including neutropenia (23%), anemia (8%), thrombocytopenia (7%), and lymphopenia (7%), developed in patients with hematologic malignancies treated with CALQUENCE. Grade 4 neutropenia developed in 12% of patients. Monitor complete blood counts regularly during treatment. Interrupt treatments reduce the dose, or discontinue treatment as warranted (see section 4.8)<em>.</em></p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Second primary malignancies</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Second primary malignancies, including skin cancers and other solid tumors, occurred in 12% of 1029 patients exposed to Calquence in clinical trials. The most frequent second primary malignancy was skin cancer, reported in 6% of patients. Monitor patients for skin cancers and advise protection from sun exposure (see section 4.8).</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><u>Atrial fibrillation</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Grade 3 atrial fibrillation or flutter occurred in 1.1% of 1029 patients treated with CALQUENCE, with all grades of atrial fibrillation or flutter reported in 4.1% of all patients [see section 4.8]. The risk may be increased in patients with cardiac risk factors, hypertension, previous arrhythmias, and acute infection. Monitor for symptoms of arrhythmia (e.g., palpitations, dizziness, syncope, dyspnea) and manage as appropriate.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Other medicinal products</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Co-administration of strong CYP3A inhibitors with Calquence may lead to increased acalabrutinib exposure and consequently a higher risk for toxicity. On the contrary, co-administration of CYP3A inducers may lead to decreased acalabrutinib exposure and consequently a risk for lack of efficacy. Concomitant use with strong CYP3A inhibitors should be avoided. If these inhibitors will be used short-term (such as anti-infectives for up to seven days), treatment with Calquence should be interrupted. Patients should be closely monitored for signs of toxicity if a moderate CYP3A inhibitor is used (see sections 4.2 and 4.5). Concomitant use with strong CYP3A4 inducers should be avoided due to risk for lack of efficacy.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Calquence contains sodium</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">This medicinal product contains less than 1 mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Acalabrutinib and its active metabolite are primarily metabolised by cytochrome P450 enzyme 3A4 (CYP3A4), and both substances are substrates for P-gp and breast cancer resistance protein (BCRP).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Active substances that may increase acalabrutinib plasma concentrations</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em>CYP3A/P-gp inhibitors</em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">Co-administration with a strong CYP3A/P-gp inhibitor (200&nbsp;mg itraconazole once daily for 5 days) increased acalabrutinib C<sub>max</sub> and AUC by 3.9-fold and 5.0-fold in healthy subjects (N=17), respectively.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Concomitant use with strong CYP3A/P-gp inhibitors should be avoided. If the strong CYP3A/<em>P-gp </em>inhibitors (e.g., ketoconazole, conivaptan, clarithromycin, indinavir, itraconazole, ritonavir, telaprevir, posaconazole, voriconazole) will be used short-term, treatment with Calquence should be interrupted (see section 4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Co-administration with moderate CYP3A inhibitors (400 mg fluconazole as single dose or 200 mg isavuconazole as repeated dose for 5 days) in healthy subjects increased acalabrutinib C<sub>max</sub> and AUC by 1.4-fold to 2-fold while the active metabolite ACP-5862 C<sub>max</sub> and AUC was decreased by 0.65-fold to 0.88-fold relative to when acalabrutinib was dosed alone. No dose adjustment is required in combination with moderate CYP3A inhibitors. Monitor patients closely for adverse reactions (see Section 4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Active substances that may decrease acalabrutinib plasma concentrations</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em>CYP3A inducers</em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">Co-administration of a strong CYP3A inducer (600&nbsp;mg rifampicin once daily for 9 days) decreased acalabrutinib C<sub>max</sub> and AUC by 68% and 77% in healthy subjects (N=24), respectively.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Concomitant use with strong inducers of CYP3A activity (e.g., phenytoin, rifampicin, carbamazepine) should be avoided. Concomitant treatment with St. John&rsquo;s wort, which may unpredictably decrease acalabrutinib plasma concentrations, should be avoided.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Gastric acid reducing medicinal products</em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">No clinically significant differences in acalabrutinib pharmacokinetics were observed when a 100 mg acalabrutinib tablet was used concomitantly with a proton pump inhibitor (rabeprazole 20 mg twice daily for 3 days). Acalabrutinib tablets can be co-administered with gastric acid reducing agents (proton pump inhibitors, H2-receptor antagonists, antacids), unlike aclabrutinib capsules which show impaired uptake when given with acid reducing agents.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Active substances whose plasma concentrations may be altered by Calquence</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em>CYP3A substrates</em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">Based on <em>in vitro</em> data, it cannot be excluded that acalabrutinib is an inhibitor of CYP3A4 at the intestinal level and may increase the exposure of CYP3A4 substrates sensitive to gut CYP3A metabolism. Caution should be exercised if co-administering acalabrutinib with CYP3A4 substrates with narrow therapeutic range administered orally (e.g., cyclosporine, ergotamine, pimozide).</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>Effect of acalabrutinib on CYP1A2 substrates </em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><em>In vitro</em> studies indicate that acalabrutinib induces CYP1A2. Co-administration of acalabrutinib with CYP1A2 substrates (e.g., theophylline, caffeine) may decrease their exposure.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Effects of acalabrutinib and its active metabolite, ACP-5862, on medicinal product transport systems</em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">Acalabrutinib may increase exposure to co-administered BCRP substrates (e.g., methotrexate) by inhibition of intestinal BCRP (see section 5.2). To minimise the potential for an interaction in the Gastrointestinal (GI) tract, oral narrow therapeutic range BCRP substrates such as methotrexate should be taken at least 6 hours before or after acalabrutinib.</p><p dir="ltr">&nbsp;</p><p dir="ltr">ACP-5862 may increase exposure to co-administered MATE1 substrates (e.g., metformin) by inhibition of MATE1 (see section 5.2). Patients taking concomitant medicinal products with disposition dependent upon MATE1 (e.g., metformin) should be monitored for signs of changed tolerability as a result of increased exposure of the concomitant medication whilst receiving Calquence.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Pregnancy Testing</u></p><p dir="ltr">Pregnancy testing is recommended for females of reproductive potential prior to initiating Calquence therapy.</p><p dir="ltr"><u>Contraception</u></p><p dir="ltr"><em>Females</em></p><p dir="ltr">Advise female patients of reproductive potential to use effective contraception during treatment with Calquence<u> </u>and for 1 week following the last dose of Calquence. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be informed of the potential hazard to a fetus.</p><p dir="ltr"><u>Breast-feeding</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">No data are available regarding the presence of acalabrutinib or its active metabolite in human milk, its effects on the breastfed child, or on milk production. Acalabrutinib and its active metabolite were present in the milk of lactating rats. Due to the potential for adverse reactions in a breastfed child from Calquence, advise lactating women not to breastfeed while taking Calquence<u> </u>and for 2 weeks after the last dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Fertility</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">In a fertility study in rats, there were no effects of acalabrutinib on fertility in male rats at exposures 11 times, or in female rats at exposures 9 times, the AUC observed in patients at the recommended dose of 100 mg twice daily. (see section 5.3).</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Calquence has no or negligible influence on the ability to drive and use machines. However, during treatment with acalabrutinib, fatigue and dizziness have been reported and patients who experience these symptoms should be advised not to drive or use machines until symptoms abate.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">As clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p dir="ltr">The data in the Warnings and Precautions reflect exposure to Calquence<u> </u>100 mg approximately every 12 hours in 1029 patients with hematologic malignancies. Treatment includes Calquence<u> </u>monotherapy in 820 patients in 6 trials, and Calquence<u> </u>with Obinutuzumab in 209 patients in 2 trials. Among these recipients of Calquence, 88% were exposed for at least 6 months and 79% were exposed for at least one year. In this pooled safety population, adverse reactions in &ge; 30% of 1029 patients were anemia, neutropenia, upper respiratory tract infection, thrombocytopenia, headache, diarrhea, and musculoskeletal pain.</p><p dir="ltr"><u>Mantle Cell Lymphoma</u></p><p dir="ltr">The safety data described in this section reflect exposure to Calquence<u> </u>(100 mg approximately every 12 hours) in 124&nbsp;patients with previously treated MCL in Trial LY-004 <em>[</em>see section 4.2<em>]</em>. The median duration of treatment with Calquence<u> </u>was 16.6 (range: 0.1 to 26.6) months. A total of 91 (73.4%) patients were treated with Calquence<u> </u>for &ge; 6 months and 74 (59.7%) patients were treated for &ge;&nbsp;1&nbsp;year.</p><p dir="ltr">The most common adverse reactions (&ge; 20%) of any grade were anemia, thrombocytopenia, headache, neutropenia, diarrhea, fatigue, myalgia, and bruising. Grade 1 severity for the non-hematologic, most common events were as follows: headache (25%), diarrhea (16%), fatigue (20%), myalgia (15%), and bruising (19%). The most common Grade &ge; 3 non-hematological adverse reaction (reported in at least 2%&nbsp;of patients) was diarrhea.</p><p dir="ltr">Dose reductions and discontinuation due to any adverse reaction were reported in 1.6% and 6.5% of patients, respectively.</p><p dir="ltr">Tables 3 and 4 present the frequency category of adverse reactions observed in patients with MCL treated with Calquence.</p><p dir="ltr"><strong>Table 3: Non-Hematologic Adverse Reactions in &ge; 5% (All Grades) of Patients with MCL in Trial LY-004</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:100%"><thead><tr><td rowspan="2"><p><strong>Body System</strong></p><p><strong>Adverse Reactions</strong><sup>*</sup></p></td><td colspan="2"><p><strong>CALQUENCE Monotherapy</strong></p><p><strong>N=124</strong></p></td></tr><tr><td><p><strong>All Grades (%)</strong></p></td><td><p><strong>Grade &ge; 3 (%)</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td><p>39</p></td><td><p>1.6</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>3.2</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td colspan="3"><p><strong>General disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td colspan="3"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Bruising<sup>a</sup></p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Rash<sup>b</sup></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhage<sup>c</sup></p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Epistaxis</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>-</p></td></tr></tbody></table><p dir="ltr"><sup>*</sup>Per NCI CTCAE version 4.03.</p><p dir="ltr"><sup>a </sup>Bruising: Includes all terms containing &lsquo;bruise,&rsquo; &lsquo;contusion,&rsquo; &lsquo;petechiae,&rsquo; or &lsquo;ecchymosis&rsquo;</p><p dir="ltr"><sup>b </sup>Rash: Includes all terms containing &lsquo;rash&rsquo;</p><p dir="ltr"><sup>c </sup>Hemorrhage: Includes all terms containing &lsquo;hemorrhage&rsquo; or &lsquo;hematoma&rsquo;</p><p dir="ltr"><strong>Table 4: Hematologic Adverse Reactions Reported in &ge; 20% of Patients with MCL in Trial LY‑004</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:100%"><tbody><tr><td rowspan="2"><p><strong>Hematologic</strong></p><p><strong>Adverse Reactions</strong><sup>*</sup></p><p><strong>&nbsp;</strong></p></td><td colspan="2"><p><strong>CALQUENCE Monotherapy</strong></p><p><strong>N=124</strong></p></td></tr><tr><td><p><strong>All Grades (%)</strong></p></td><td><p><strong>Grade &ge; 3 (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hemoglobin decreased</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>Platelets decreased</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>Neutrophils decreased</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>15</p></td></tr></tbody></table><p dir="ltr"><sup>*</sup>Per NCI CTCAE version 4.03; based on laboratory measurements and adverse reactions.</p><p dir="ltr">Increases in creatinine to 1.5 to 3 times the upper limit of normal (ULN) occurred in 4.8% of patients.</p><p dir="ltr"><u>Chronic Lymphocytic Leukemia</u></p><p dir="ltr">The safety data described below reflect exposure to Calquence<u> </u>(100 mg approximately every 12 hours, with or without Obinutuzumab) in 511 patients with CLL from two randomized controlled clinical trials (See section 4.2).</p><p dir="ltr">The most common adverse reactions (&ge; 30%) of any grade in patients with CLL were anemia, neutropenia, thrombocytopenia, headache, upper respiratory tract infection, and diarrhea.</p><p dir="ltr"><em>ELEVATE-TN</em></p><p dir="ltr">The safety of Calquence<u> </u>plus Obinutuzumab (Calquence<u> </u>+G), Calquence<u> </u>monotherapy, and Obinutuzumab plus chlorambucil (GClb) was evaluated in a randomized, multicenter, open-label, actively controlled trial in 526 patients with previously untreated CLL (See section 4.2).</p><p dir="ltr">Patients randomized to the CALQUENCE+G arm were treated with CALQUENCE and Obinutuzumab in combination for six cycles, then with CALQUENCE as monotherapy until disease progression or unacceptable toxicity. Patients initiated Obinutuzumab on Day 1 of Cycle 2, continuing for a total of 6 cycles. Patient randomized to CALQUENCE monotherapy received CALQUENCE approximately every 12 hours until disease progression or unacceptable toxicity. The trial required age &ge; 65 years of age or 18 to &lt; 65 years of age with a total Cumulative Illness Rating Scale (CIRS) &gt; 6 or creatinine clearance of 30 to 69 mL/min, hepatic transaminases &le; 3 times ULN and total bilirubin &le; 1.5 times ULN, and allowed patients to receive antithrombotic agents other than warfarin or equivalent vitamin K antagonists.</p><p dir="ltr">During randomized treatment, the median duration of exposure to CALQUENCE in the CALQUENCE+G and CALQUENCE monotherapy arms was 27.7 months (range 0.3 to 40 months), with 95% and 92% and 89% and 86% of patients with at least 6 months and 12 months of exposure, respectively. In the Obinutuzumab and chlorambucil arm the median number of cycles was 6 with 84% of patients receiving at least 6 cycles of Obinutuzumab, 70% of patients received at least 6 cycles of chlorambucil. Eighty-five percent of patients in the CALQUENCE+G arm received at least 6 cycles of Obinutuzumab.</p><p dir="ltr">In the CALQUENCE+G and CALQUENCE monotherapy arms, fatal adverse reactions that occurred in the absence of disease progression and with onset within 30 days of the last study treatment were reported in 2% for each treatment arm, most often from infection. Serious adverse reactions were reported in 39% of patients in the CALQUENCE+G arm and 32% in the CALQUENCE monotherapy arm, most often due to events of pneumonia (2.8% to 7%).</p><p dir="ltr">In the CALQUENCE+G arm, adverse reactions led to treatment discontinuation in 11% of patients and a dose reduction of CALQUENCE in 7% of patients. In the CALQUENCE monotherapy arm, adverse reactions led to discontinuation in 10% and dose reduction in 4% of patients.</p><p dir="ltr">Tables 5 and 6 present adverse reactions and laboratory abnormalities identified in the ELEVATE-TN trial.</p><p dir="ltr"><strong>Table 5: Common Adverse Reactions (&ge; 15% Any Grade) with CALQUENCE in Patients with CLL (ELEVATE-TN)</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:100%"><thead><tr><td rowspan="2"><p><strong>Body System</strong></p><p><strong>Adverse Reaction</strong><sup>*</sup></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>CALQUENCE plus Obinutuzumab<br />N=178</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>CALQUENCE Monotherapy</strong></p><p><strong>N=179</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Obinutuzumab plus Chlorambucil<br />N=169</strong></p></td></tr><tr><td><p><strong>All Grades (%)</strong></p></td><td><p><strong>Grade &ge; 3 (%)</strong></p></td><td><p><strong>All Grades (%)</strong></p></td><td><p><strong>Grade &ge; 3 (%)</strong></p></td><td><p><strong>All Grades (%)</strong></p></td><td><p><strong>Grade &ge; 3 (%)</strong></p></td></tr></thead><tbody><tr><td colspan="7" style="vertical-align:bottom"><p><strong>Infections </strong></p></td></tr><tr><td style="vertical-align:top"><p>Infection<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>69</p></td><td style="vertical-align:top"><p>22<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>65</p></td><td style="vertical-align:top"><p>14<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>13<sup>&Dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>1.2</p></td></tr><tr><td style="vertical-align:top"><p>Lower respiratory tract infection<sup>a</sup></p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>4.5</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>1.8</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td colspan="7" style="vertical-align:bottom"><p><strong>Blood and lymphatic system disorders</strong><sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia<sup>c</sup></p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>78</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p>Anemia<sup>d</sup></p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>54</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>e</sup></p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>3.4</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>16</p></td></tr><tr><td style="vertical-align:top"><p>Lymphocytosis<sup>f</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>4.5</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>1.8</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain<sup>g</sup></p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>2.4</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>4.7</p></td><td style="vertical-align:top"><p>1.2</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>h</sup></p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>1.2</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Bruising<sup>i</sup></p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Rash<sup>j</sup></p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhage<sup>k</sup><sup> </sup></p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p dir="ltr"><sup>*</sup>Per NCI CTCAE version 4.03</p><p dir="ltr"><sup>&dagger;</sup><sup> </sup>Includes any adverse reactions involving infection or febrile neutropenia</p><p dir="ltr"><sup>&Dagger;</sup> Includes 3 fatal cases in the CALQUENCE plus obinutuzumab arm, 3 fatal cases in the CALQUENCE monotherapy arm and 1 fatal case in the obinutuzumab plus chlorambucil arm</p><p dir="ltr"><sup>&sect;</sup> Includes upper respiratory tract infection, nasopharyngitis and sinusitis</p><p dir="ltr"><sup>a</sup><sup> </sup>Includes pneumonia, lower respiratory tract infection, bronchitis, bronchiolitis, tracheitis, and lung infection</p><p dir="ltr"><sup>b </sup>Derived from adverse reaction and laboratory data</p><p dir="ltr"><sup>c</sup> Includes neutropenia, neutrophil count decreased, and related laboratory data</p><p dir="ltr"><sup>d</sup> Includes anemia, red blood cell count decreased, and related laboratory data</p><p dir="ltr"><sup>e </sup>Includes thrombocytopenia, platelet count decreased, and related laboratory data</p><p dir="ltr"><sup>f</sup> Includes lymphocytosis, lymphocyte count increased, and related laboratory data</p><p dir="ltr"><sup>g</sup><sup> </sup>Includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity and spinal pain</p><p dir="ltr"><sup>h</sup><sup> </sup>Includes asthenia, fatigue, and lethargy</p><p dir="ltr"><sup>i</sup> Includes bruise, contusion, and ecchymosis</p><p dir="ltr"><sup>j</sup> Includes rash, dermatitis, and other related terms</p><p dir="ltr"><sup>k</sup><sup> </sup>Includes hemorrhage, hematoma, hemoptysis, hematuria, menorrhagia, hemarthrosis, and epistaxis</p><p dir="ltr">&nbsp;</p><p dir="ltr">Other clinically relevant adverse reactions (all grades incidence &lt; 15%) in recipients of CALQUENCE (CALQUENCE in combination with obinutuzumab and monotherapy) included:</p><p dir="ltr"><em>Neoplasms</em><em>:</em> second primary malignancy (10%), non-melanoma skin cancer (5%)</p><p dir="ltr"><em>Cardiac disorders:</em> atrial fibrillation or flutter (3.6%), hypertension (5%)</p><p dir="ltr"><em>Infection:</em> herpesvirus infection (6%)</p><p dir="ltr"><strong>Table 6: Select Non-Hematologic Laboratory Abnormalities (&ge; 15% Any Grade), New or Worsening from Baseline in Patients Receiving CALQUENCE (ELEVATE-TN)</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:100%"><thead><tr><td rowspan="2"><p><strong>Laboratory Abnormality<sup>*,a</sup></strong></p></td><td colspan="2"><p><strong>CALQUENCE plus Obinutuzumab</strong></p><p><strong>N=178</strong></p></td><td colspan="2"><p><strong>CALQUENCE Monotherapy</strong></p><p><strong>N=179</strong></p></td><td colspan="2"><p><strong>Obinutuzumab plus Chlorambucil</strong></p><p><strong>N=169</strong></p></td></tr><tr><td><p><strong>All Grades (%)</strong></p></td><td><p><strong>Grade &ge; 3</strong></p><p><strong>(%)</strong></p></td><td><p><strong>All Grades (%)</strong></p></td><td><p><strong>Grade &ge; 3</strong></p><p><strong>(%)</strong></p></td><td><p><strong>All Grades (%)</strong></p></td><td><p><strong>Grade &ge; 3</strong></p><p><strong>(%)</strong></p></td></tr></thead><tbody><tr><td><p><strong>Uric acid increase</strong></p></td><td><p>29</p></td><td><p>29</p></td><td><p>22</p></td><td><p>22</p></td><td><p>37</p></td><td><p>37</p></td></tr><tr><td><p><strong>ALT increase</strong></p></td><td><p>30</p></td><td><p>7</p></td><td><p>20</p></td><td><p>1.1</p></td><td><p>36</p></td><td><p>6</p></td></tr><tr><td><p><strong>AST increase</strong></p></td><td><p>38</p></td><td><p>5</p></td><td><p>17</p></td><td><p>0.6</p></td><td><p>60</p></td><td><p>8</p></td></tr><tr><td><p><strong>Bilirubin increase</strong></p></td><td><p>13</p></td><td><p>0.6</p></td><td><p>15</p></td><td><p>0.6</p></td><td><p>11</p></td><td><p>0.6</p></td></tr></tbody></table><p dir="ltr"><sup>*</sup>Per NCI CTCAE version 4.03</p><p dir="ltr"><sup>a</sup> Excludes electrolytes</p><p dir="ltr">Increases in creatinine to 1.5 to 3 times ULN occurred in 3.9% and 2.8% of patients in the CALQUENCE combination arm and monotherapy arm, respectively.</p><p dir="ltr"><em>ASCEND</em></p><p dir="ltr">The safety of CALQUENCE in patients with relapsed or refractory CLL was evaluated in a randomized, open-label study (ASCEND) (See section 4.2).The trial enrolled patients with relapsed or refractory CLL after at least one prior therapy and required hepatic transaminases &le; 2 times ULN, total bilirubin &le; 1.5 times ULN, and an estimated creatinine clearance &ge; 30 mL/min. The trial excluded patients having an absolute neutrophil count &lt; 500/&micro;L, platelet count &lt; 30,000/&micro;L, prothrombin time or activated partial thromboplastin time &gt; 2 times ULN, significant cardiovascular disease, or a requirement for strong CYP3A inhibitors or inducers. Patients were allowed to receive antithrombotic agents other than warfarin or equivalent vitamin K antagonist.</p><p dir="ltr">In ASCEND, 154 patients received CALQUENCE (100 mg approximately every 12 hours until disease progression or unacceptable toxicity), 118 received idelalisib (150 mg approximately every 12 hours until disease progression or unacceptable toxicity) with up to 8 infusions of a rituximab product, and 35 received up to 6 cycles of bendamustine and a rituximab product. The median age overall was 68 years (range: 32-90); 67% were male; 92% were white; and 88% had an ECOG performance status of 0 or 1.</p><p dir="ltr">In the CALQUENCE arm, serious adverse reactions occurred in 29% of patients. Serious adverse reactions in &gt; 5% of patients who received CALQUENCE included lower respiratory tract infection (6%). Fatal adverse reactions within 30 days of the last dose of CALQUENCE occurred in 2.6% of patients, including from second primary malignancies and infection.</p><p dir="ltr">In recipients of CALQUENCE, permanent discontinuation due to an adverse reaction occurred in 10% of patients, most frequently due to second primary malignancies followed by infection. Adverse reactions led to dosage interruptions of CALQUENCE in 34% of patients, most often due to respiratory tract infections followed by neutropenia, and dose reduction in 3.9% of patients.</p><p dir="ltr">Selected adverse reactions are described in Table 7 and non-hematologic laboratory abnormalities are described in Table 8. These tables reflect exposure to CALQUENCE with median duration of 15.7 months with 94% of patients on treatment for greater than 6 months and 86% of patients on treatment for greater than 12 months. The median duration of exposure to idelalisib was 11.5 months with 72% of patients on treatment for greater than 6 months and 48% of patients on treatment for greater than 12 months. Eighty-three percent of patients completed 6 cycles of bendamustine and rituximab product.</p><p dir="ltr"><strong>Table 7: Common Adverse Reactions (&ge; 15% Any Grade) with CALQUENCE in Patients with CLL (ASCEND)</strong></p><table border="1" cellspacing="0" cellpadding="0" align="left" dir="ltr" style="width:100%"><thead><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Body System</strong></p><p><strong>Adverse Reaction<sup>*</sup></strong></p></td><td colspan="2"><p><strong>CALQUENCE</strong></p><p><strong>N=154</strong></p></td><td colspan="2"><p><strong>Idelalisib plus Rituximab</strong></p><p><strong>Product N=118</strong></p></td><td colspan="2"><p><strong>Bendamustine plus Rituximab Product</strong></p><p><strong>N=35</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>All Grades (%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade &ge; 3 (%)</strong></p></td><td style="vertical-align:bottom"><p><strong>All Grades (%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade &ge; 3 (%)</strong></p></td><td style="vertical-align:bottom"><p><strong>All Grades (%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade &ge; 3 (%)</strong></p></td></tr><tr><td colspan="7" style="vertical-align:bottom"><p><strong>Infections </strong></p></td></tr><tr><td style="vertical-align:top"><p>Infection<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>56</p></td><td style="vertical-align:top"><p>15<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>65</p></td><td style="vertical-align:top"><p>28<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>49</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>3.4</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>2.9</p></td></tr><tr><td style="vertical-align:top"><p>Lower respiratory tract infection<sup> a</sup></p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td colspan="7" style="vertical-align:bottom"><p><strong>Blood and lymphatic system disorders</strong><strong><sup>b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia<sup>c</sup></p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>79</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>40</p></td></tr><tr><td style="vertical-align:top"><p>Anemia<sup>d</sup></p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>17</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>e</sup></p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>54</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Lymphocytosis<sup>f</sup></p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>2.9</p></td><td style="vertical-align:top"><p>2.9</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea<sup>g</sup></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>49</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhage<sup>h </sup></p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>2.9</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>General disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>i</sup></p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain<sup>j</sup></p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>2.9</p></td><td style="vertical-align:top"><p>0</p></td></tr></thead></table><p dir="ltr"><sup>*</sup> Per NCI CTCAE version 4.03</p><p dir="ltr"><sup>&dagger;</sup> Includes any adverse reactions involving infection or febrile neutropenia</p><p dir="ltr"><sup>&Dagger;</sup> Includes 1 fatal case in the CALQUENCE monotherapy arm and 1 fatal case in the Idelalisib plus Rituximab arm</p><p dir="ltr"><sup>&sect;</sup> Includes upper respiratory tract infection, rhinitis and nasopharyngitis</p><p dir="ltr"><sup>a</sup> Includes pneumonia, lower respiratory tract infection, bronchitis, bronchiolitis, tracheitis, and lung infection.</p><p dir="ltr"><sup>b</sup> Derived from adverse reaction and laboratory data</p><p dir="ltr"><sup>c</sup> Includes neutropenia, neutrophil count decreased, and related laboratory data</p><p dir="ltr"><sup>d</sup> Includes anemia, red blood cell decreased, and related laboratory data</p><p dir="ltr"><sup>e</sup> Includes thrombocytopenia, platelet count decreased, and related laboratory data</p><p dir="ltr"><sup>f</sup> Includes lymphocytosis, lymphocyte count increased and related laboratory data</p><p dir="ltr"><sup>g</sup> Includes colitis, diarrhea, and enterocolitis</p><p dir="ltr"><sup>h</sup> Includes hemorrhage, hematoma, hemoptysis, hematuria, menorrhagia, hemarthrosis, and epistaxis</p><p dir="ltr"><sup>i</sup> Includes asthenia, fatigue, and lethargy</p><p dir="ltr"><sup>j</sup> Includes back pain, musculoskeletal chest pain, musculoskeletal pain, musculoskeletal discomfort, pain in extremity, myalgia, spinal pain and bone pain</p><p dir="ltr">&nbsp;</p><p dir="ltr">Other clinically relevant adverse reactions (all grades incidence &lt; 15%) in recipients of CALQUENCE included:</p><p dir="ltr"><em>Skin and subcutaneous disorders:</em> bruising (10%), rash (9%)</p><p dir="ltr"><em>Neoplasms:</em> second primary malignancy (12%), non-melanoma skin cancer (6%)</p><p dir="ltr"><em>Musculoskeletal and connective tissue disorders:</em><strong> </strong>arthralgia (8%)</p><p dir="ltr"><em>Cardiac disorders:</em> atrial fibrillation or flutter (5%), hypertension (3.2%)</p><p dir="ltr"><em>Infection:</em> herpesvirus infection (4.5%)</p><p dir="ltr"><strong>Table 8: Select Non-Hematologic Laboratory Abnormalities<sup> </sup>(&ge; 10% Any Grade), New or Worsening from Baseline in Patients Receiving CALQUENCE (ASCEND)</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:100%"><thead><tr><td rowspan="2"><p><strong>Laboratory Abnormality <sup>a</sup></strong></p></td><td colspan="2"><p><strong>CALQUENCE</strong></p><p><strong>N=154</strong></p></td><td colspan="2"><p><strong>Idelalisib plus Rituximab Product</strong></p><p><strong>N=118</strong></p></td><td colspan="2"><p><strong>Bendamustine plus Rituximab Product</strong></p><p><strong>N=35</strong></p></td></tr><tr><td><p><strong>All Grades (%)</strong></p></td><td><p><strong>Grade &ge; 3 (%)</strong></p></td><td><p><strong>All Grades (%)</strong></p></td><td><p><strong>Grade &ge; 3 (%)</strong></p></td><td><p><strong>All Grades (%)</strong></p></td><td><p><strong>Grade &ge; 3 (%)</strong></p></td></tr></thead><tbody><tr><td><p>Uric acid increase</p></td><td><p>15</p></td><td><p>15</p></td><td><p>11</p></td><td><p>11</p></td><td><p>23</p></td><td><p>23</p></td></tr><tr><td><p>ALT increase</p></td><td><p>15</p></td><td><p>1.9</p></td><td><p>59</p></td><td><p>23</p></td><td><p>26</p></td><td><p>2.9</p></td></tr><tr><td><p>AST increase</p></td><td><p>13</p></td><td><p>0.6</p></td><td><p>48</p></td><td><p>13</p></td><td><p>31</p></td><td><p>2.9</p></td></tr><tr><td><p>Bilirubin increase</p></td><td><p>13</p></td><td><p>1.3</p></td><td><p>16</p></td><td><p>1.7</p></td><td><p>26</p></td><td><p>11</p></td></tr></tbody></table><p dir="ltr">Per NCI CTCAE version 5</p><p dir="ltr"><sup>a</sup> Excludes electrolytes</p><p dir="ltr">&nbsp;</p><p dir="ltr">Increases in creatinine to 1.5 to 3 times ULN occurred in 1.3% of patients who received CALQUENCE.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">To report any side effect(s):</p><ul dir="ltr"><li><strong><em>Saudi Arabia: </em></strong></li></ul><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>- </strong>The National Pharmacovigilance Centre (NPC)</p><ul><li>Toll free phone: 19999</li><li>E-mail: npc.drug@sfda.gov.sa&nbsp;&nbsp;</li><li>Website: https://ade.sfda.gov.sa/</li></ul><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><ul dir="ltr"><li>Other GCC States:</li></ul><p dir="ltr">&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">There is no specific treatment for acalabrutinib overdose and symptoms of overdose have not been established. In the event of an overdose, patients must be closely monitored for signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01EL02.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Mechanism of action</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Acalabrutinib is a small-molecule inhibitor of Bruton tyrosine kinase (BTK). Acalabrutinib and its active metabolite, ACP-5862, form a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B&nbsp;cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. In nonclinical studies, acalabrutinib inhibited BTK‑mediated&nbsp;activation of downstream signaling proteins CD86 and CD69 and inhibited malignant B- cell proliferation and tumor growth in mouse xenograft models.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><br /><u>Pharmacodynamic effects</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">In patients with B-cell malignancies dosed with acalabrutinib 100 mg approximately every 12 hours, median steady state BTK occupancy of &ge; 95% in peripheral blood was maintained over 12 hours, resulting in inactivation of BTK throughout the recommended dosing interval.</p><p dir="ltr"><u>Cardiac Electrophysiology</u></p><p dir="ltr">At a dose 4 times the approved recommended dosage, CALQUENCE does not prolong the QTc interval to any clinically relevant extent</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Cardiac electrophysiology</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">At a dose 4 times the approved recommended dosage, CALQUENCE does not prolong the QTc interval to any clinically relevant extent</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Clinical efficacy and safety</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">The efficacy of CALQUENCE was based upon Trial LY-004 titled &ldquo;An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma&rdquo; (NCT02213926). Trial LY-004 enrolled a total of 124&nbsp;patients with MCL who had received at least one prior therapy.</p><p dir="ltr">The median age was 68 (range 42 to 90) years, 80% were male, and 74% were Caucasian. At baseline, 93% of patients had an ECOG performance status of 0 or 1. The median time since diagnosis was 46.3&nbsp;months and the median number of prior treatments was 2 (range 1 to 5), including 18% with prior stem cell transplant. Patients who received prior treatment with BTK inhibitors were excluded. The most common prior regimens were CHOP-based (52%) and ARA-C (34%). At baseline, 37% of patients had at least one tumor with a longest diameter &ge; 5 cm, 73% had extra nodal involvement including 51% with bone marrow involvement. The simplified Mantle Cell Lymphoma International Prognostic Index (MIPI) score (which includes age, ECOG score, and baseline lactate dehydrogenase and white cell count) was intermediate in 44% and high in 17% of patients.</p><p dir="ltr">CALQUENCE was administered orally at 100 mg approximately every 12 hours until disease progression or unacceptable toxicity. The median dose intensity was 98.5%. The major efficacy outcome of Trial LY-004 was overall response rate and the median follow-up was 15.2 months.</p><p dir="ltr"><strong>Table 9: Efficacy Results in Patients with MCL in Trial LY-004</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p><strong>Investigator Assessed</strong></p><p><strong>N=124</strong></p></td><td><p><strong>Independent Review Committee (IRC) Assessed</strong></p><p><strong>N=124</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Overall Response Rate<sup> </sup>(ORR)<sup>*</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;ORR (%) [95% CI]</p></td><td style="vertical-align:top"><p>81 [73, 87]</p></td><td style="vertical-align:top"><p>80 [72, 87]</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;Complete Response (%) [95% CI]</p></td><td style="vertical-align:top"><p>40 [31, 49]</p></td><td style="vertical-align:top"><p>40 [31, 49]</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;Partial Response (%) [95% CI]</p></td><td style="vertical-align:top"><p>41 [32, 50]</p></td><td style="vertical-align:top"><p>40 [32, 50]</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Duration of Response (DoR)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;Median DoR in months [range]</p></td><td style="vertical-align:top"><p>NE [1+ to 20+]</p></td><td style="vertical-align:top"><p>NE [0+ to 20+]</p></td></tr></tbody></table><p dir="ltr">CI= Confidence Interval; NE=Not Estimable; + indicates censored observations.</p><p dir="ltr"><sup>*</sup>Per 2014 Lugano Classification.</p><p dir="ltr">The median time to best response was 1.9 months.</p><p dir="ltr"><u>Lymphocytosis</u></p><p dir="ltr">Upon initiation of CALQUENCE, a temporary increase in lymphocyte counts (defined as absolute lymphocyte count increased &ge; 50% from baseline and a post-baseline assessment &ge; 5 x 10<sup>9</sup>/L) in 31.5% of patients in Trial LY-004. The median time to onset of lymphocytosis was 1.1 weeks, and the median duration of lymphocytosis was 6.7 weeks.</p><p dir="ltr"><strong>14.2 Chronic Lymphocytic Leukemia</strong></p><p dir="ltr">The efficacy of CALQUENCE in patients with CLL was demonstrated in two randomized, controlled trials. The indication for CALQUENCE includes patients with SLL because it is the same disease.</p><p dir="ltr"><em>ELEVATE-TN</em></p><p dir="ltr">The efficacy of CALQUENCE was evaluated in the ELEVATE-TN trial, a randomized, multicenter, open-label, actively controlled, 3 arm trial of CALQUENCE in combination with obinutuzumab, CALQUENCE monotherapy, and obinutuzumab in combination with chlorambucil in 535 patients with previously untreated chronic lymphocytic leukemia (NCT02475681). Patients 65 years of age or older or between 18 and 65 years of age with a total Cumulative Illness Rating Scale (CIRS) &gt; 6 or creatinine clearance of 30 to 69 mL/min were enrolled. The trial also required hepatic transaminases &le; 3 times upper limit of normal (ULN) and total bilirubin &le; 1.5 times ULN, and excluded patients with Richter&rsquo;s transformation.</p><p dir="ltr">Patients were randomized in a 1:1:1 ratio into 3 arms to receive:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CALQUENCE plus obinutuzumab (CALQUENCE+G): CALQUENCE 100 mg was administered approximately every 12 hours starting on Cycle 1 Day 1 until disease progression or unacceptable toxicity. Obinutuzumab was administered starting on Cycle 2 Day 1 for a maximum of 6 treatment cycles. Obinutuzumab 1,000 mg was administered on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of Cycle 2 followed by 1,000 mg on Day 1 of Cycles 3 up to 7. Each cycle was 28 days.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CALQUENCE monotherapy: CALQUENCE 100 mg was administered approximately every 12 hours until disease progression or unacceptable toxicity.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Obinutuzumab plus chlorambucil (GClb): Obinutuzumab and chlorambucil were administered for a maximum of 6 treatment cycles. Obinutuzumab 1,000 mg was administered intravenously on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of Cycle 1 followed by 1,000 mg on Day 1 of Cycles 2 to 6. Chlorambucil 0.5 mg/kg was administered orally on Days 1 and 15 of Cycles 1 to 6. Each cycle was 28 days.</p><p dir="ltr">Randomization was stratified by 17p deletion mutation status, ECOG performance status (0 or 1 versus 2), and geographic region. A total of 535 patients were randomized, 179 to CALQUENCE+G, 179 to CALQUENCE monotherapy, and 177 to GClb. The overall median age was 70 years (range: 41 to 91 years), 47% had Rai stage III or IV disease, 14% had 17p deletion or TP53 mutation, 63% of patients had an unmutated IGVH, and 18% had 11q deletion. Baseline demographic and disease characteristics were similar between treatment arms.</p><p dir="ltr">Efficacy was based on progression-free survival (PFS) as assessed by an Independent Review Committee (IRC). The median duration of follow-up was 28.3 months (range: 0.0 to 40.8 months). Efficacy results are presented in Table&nbsp;10. The Kaplan-Meier curves for PFS are shown in Figure 1.</p><p dir="ltr"><strong>Table 10. Efficacy Results per IRC in Patients with CLL </strong><strong>‒</strong><strong> ITT population (ELEVATE-TN)</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>CALQUENCE plus Obinutuzumab</strong></p><p><strong>N=179</strong></p></td><td style="vertical-align:top"><p><strong>CALQUENCE Monotherapy</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=179</strong></p></td><td style="vertical-align:top"><p><strong>Obinutuzumab plus C</strong><strong>hlorambucil</strong></p><p><strong>N=177</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Progression-Free Survival <sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of events (%)</p></td><td style="vertical-align:top"><p>14 (8)</p></td><td style="vertical-align:top"><p>26 (15)</p></td><td style="vertical-align:top"><p>93 (53)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; PD, n (%)</p></td><td style="vertical-align:top"><p>9 (5)</p></td><td style="vertical-align:top"><p>20 (11)</p></td><td style="vertical-align:top"><p>82 (46)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Death events, n (%)</p></td><td style="vertical-align:top"><p>5 (3)</p></td><td style="vertical-align:top"><p>6 (3)</p></td><td style="vertical-align:top"><p>11 (6)</p></td></tr><tr><td style="vertical-align:top"><p>Median (95% CI), months<sup> b</sup></p></td><td style="vertical-align:top"><p>NE</p></td><td style="vertical-align:top"><p>NE (34, NE)</p></td><td style="vertical-align:top"><p>22.6 (20, 28)</p></td></tr><tr><td style="vertical-align:top"><p>HR<sup>c</sup> (95% CI)</p></td><td style="vertical-align:top"><p>0.10 (0.06, 0.17)</p></td><td style="vertical-align:top"><p>0.20 (0.13, 0.30)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>p-value <sup>d</sup></p></td><td style="vertical-align:top"><p>&lt; 0.0001</p></td><td style="vertical-align:top"><p>&lt; 0.0001</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Overall Response Rate<sup>a</sup> (CR + CRi + nPR + PR)</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR, n (%)</p></td><td style="vertical-align:top"><p>168 (94)</p></td><td style="vertical-align:top"><p>153 (86)</p></td><td style="vertical-align:top"><p>139 (79)</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI)</p></td><td style="vertical-align:top"><p>(89, 97)</p></td><td style="vertical-align:top"><p>(80, 90)</p></td><td style="vertical-align:top"><p>(72, 84)</p></td></tr><tr><td style="vertical-align:top"><p>p-value <sup>e</sup></p></td><td style="vertical-align:top"><p>&lt; 0.0001</p></td><td style="vertical-align:top"><p>0.0763</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>CR, n (%)</p></td><td style="vertical-align:top"><p>23 (13)</p></td><td style="vertical-align:top"><p>1 (1)</p></td><td style="vertical-align:top"><p>8 (5)</p></td></tr><tr><td style="vertical-align:top"><p>CRi, n (%)</p></td><td style="vertical-align:top"><p>1 (1)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>nPR, n (%)</p></td><td style="vertical-align:top"><p>1 (1)</p></td><td style="vertical-align:top"><p>2 (1)</p></td><td style="vertical-align:top"><p>3 (2)</p></td></tr><tr><td style="vertical-align:top"><p>PR, n (%)</p></td><td style="vertical-align:top"><p>143 (80)</p></td><td style="vertical-align:top"><p>150 (84)</p></td><td style="vertical-align:top"><p>128 (72)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>ITT=intent-to-treat; CI=confidence interval; HR=hazard ratio; NE=not estimable; CR=complete response; CRi=complete response with incomplete blood count recovery; nPR=nodular partial response; PR=partial response.</p><p><sup>a </sup>Per 2008 International Workshop on CLL (IWCLL) criteria.</p><p><sup>b</sup> Kaplan-Meier estimate.</p><p><sup>c </sup>Based on a stratified Cox-Proportional-Hazards model. Both hazard ratios are compared with the obinutuzumab and chlorambucil arm.</p><p><sup>d</sup> Based on a stratified log-rank test, with an alpha level of 0.012 derived from alpha spending function by the O&rsquo;Brien-Fleming method.</p><p><sup>e</sup> Based on a stratified Cochran&ndash;Mantel&ndash;Haenszel test, for the comparison with the obinutuzumab and chlorambucil arm.</p></td></tr></tbody></table><p dir="ltr"><strong>Figure 1: Kaplan-Meier Curve of IRC-Assessed PFS in Patients with CLL in ELEVATE-TN</strong></p><p dir="ltr"><strong><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_3" o:spid="_x0000_i1026" type="#_x0000_t75"
 style='width:468pt;height:280.2pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="624" height="374" src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></strong></p><p dir="ltr">With a median follow-up of 28.3 months, median overall survival was not reached in any arm, with fewer than 10% of patients experiencing an event.</p><p dir="ltr"><em>ASCEND</em></p><p dir="ltr">The efficacy of CALQUENCE in patients with relapsed or refractory CLL was based upon a multicenter, randomized, open-label trial (ASCEND; NCT02970318). The trial enrolled 310 patients with relapsed or refractory CLL after at least 1 prior systemic therapy. The trial excluded patients with transformed disease, prolymphocytic leukemia, or previous treatment with venetoclax, a Bruton tyrosine kinase inhibitor, or a phosphoinositide-3 kinase inhibitor.</p><p dir="ltr">Patients were randomized in a 1:1 ratio to receive either:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CALQUENCE 100 mg approximately every 12 hours until disease progression or unacceptable toxicity, or</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Investigator&rsquo;s choice:</p><p dir="ltr">o&nbsp;&nbsp; Idelalisib plus a rituximab product (IR): Idelalisib 150 mg orally approximately every 12 hours until disease progression or unacceptable toxicity, in combination with 8 infusions of a rituximab product (375 mg/m<sup>2</sup> intravenously on Day 1 of Cycle 1, followed by 500 mg/m<sup>2</sup> every 2 weeks for 4 doses and then every 4 weeks for 3 doses), with a 28-day cycle length.</p><p dir="ltr">o&nbsp;&nbsp; Bendamustine plus a rituximab product (BR): Bendamustine 70 mg/m<sup>2</sup> intravenously (Day 1 and 2 of each 28-day cycle), in combination with a rituximab product (375&nbsp;mg/m<sup>2 </sup>intravenously on Day 1 of Cycle 1, then 500 mg/m<sup>2 </sup>on Day 1 of subsequent cycles), for up to 6 cycles.</p><p dir="ltr">Randomization was stratified by 17p deletion mutation status, ECOG performance status (0 or 1 versus 2), and number of prior therapies (1 to 3 versus &ge; 4). Of 310 patients total, 155 were assigned to CALQUENCE monotherapy, 119 to IR, and 36 to BR. The median age overall was 67 years (range: 32 to 90 years), 42% had Rai stage III or IV disease, 28% had 17p deletion or TP53 mutation, 78% of patients had an unmutated IGVH, and 27% had a 11q deletion. The CALQUENCE arm had a median of 1 prior therapy (range: 1 to 8), with 47% having at least 2 prior therapies. The investigator&rsquo;s choice arm had a median of 2 prior therapies (range: 1 to 10), with 57% having at least 2 prior therapies.</p><p dir="ltr">In the CALQUENCE arm, the median treatment duration was 15.7 months, with 94% of patients treated for at least 6 months and 86% of patients treated for at least 1 year. In the investigator&rsquo;s choice arm, the median treatment duration was 8.4 months, with 59% of patients treated for at least 6 months and 37% treated for at least 1 year.</p><p dir="ltr">Efficacy was based on PFS as assessed by an IRC, with a median follow-up of 16.1&nbsp;months (range 0.03 to 22.4 months). Efficacy results are presented in Table 11. The Kaplan-Meier curve for PFS is shown in Figure 2. There was no statistically significant difference in overall response rates between the two treatment arms.</p><p dir="ltr"><strong>Table 11: Efficacy Results per IRC in Patients with Relapsed or Refractory CLL &ndash; ITT Population (ASCEND)</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>CALQUENCE Monotherapy</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=155</strong></p></td><td style="vertical-align:top"><p><strong>Investigator&rsquo;s Choice of Idelalisib + Rituximab Product or Bendamustine + Rituximab Product</strong></p><p><strong>N=155</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Progression-Free Survival </strong><sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Number of events, n (%)</p></td><td style="vertical-align:top"><p>27 (17)</p></td><td style="vertical-align:top"><p>68 (44)</p></td></tr><tr><td style="vertical-align:top"><p>Disease progression, n</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>59</p></td></tr><tr><td style="vertical-align:top"><p>Death, n</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>Median (95% CI), months<sup> b</sup></p></td><td style="vertical-align:top"><p>NE (NE, NE)</p></td><td style="vertical-align:top"><p>16.5 (14.0, 17.1)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)<sup> c</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.31 (0.20, 0.49)</p></td></tr><tr><td style="vertical-align:top"><p>P-value <sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt; 0.0001</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Overall Response Rate (CR + CRi + nPR + PR) <sup>a, e</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR, n (%) <strong><sup>e</sup></strong></p></td><td style="vertical-align:top"><p>126 (81)</p></td><td style="vertical-align:top"><p>117 (75)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;(95% CI)</p></td><td style="vertical-align:top"><p>(74, 87)</p></td><td style="vertical-align:top"><p>(68, 82)</p></td></tr><tr><td style="vertical-align:top"><p>CR, n (%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2 (1)</p></td></tr><tr><td style="vertical-align:top"><p>CRi, n (%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>nPR, n (%)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>PR, n (%)</p></td><td style="vertical-align:top"><p>126 (81)</p></td><td style="vertical-align:top"><p>115 (74)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>ITT=intent-to-treat; CI=confidence interval; HR=hazard ratio; NE=not estimable; CR=complete response; CRi=complete response with incomplete blood count recovery; nPR=nodular partial response; PR=partial response</p><p><sup>a </sup>Per 2008 IWCLL criteria.</p><p><sup>b</sup> Kaplan-Meier estimate.</p><p><sup>c </sup>Based on a stratified Cox-Proportional-Hazards model.</p><p><sup>d</sup> Based on a stratified Log-rank test. The pre-specified type I error rate (&alpha;) for this interim analysis is 0.012 derived from a Lan-DeMets alpha spending function with O&rsquo;Brien-Fleming boundary.</p><p><sup>e </sup>Through a hierarchical testing procedure, the difference in ORR was not statistically significant, based on a Cochran-Mantel-Haenszel test with adjustment for randomization stratification factors.</p></td></tr></tbody></table><p dir="ltr"><strong>Figure 2: Kaplan-Meier Curve of IRC-Assessed PFS in Patients with CLL in ASCEND</strong></p><p dir="ltr"><strong><!--[if gte vml 1]><v:shape
 id="Picture_x0020_2" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:471.6pt;
 height:295.8pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image003.emz"
  o:title=""/>
</v:shape><![endif]--><img width="629" height="394" src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></strong></p><p dir="ltr">With a median follow-up of 16.1 months, median overall survival was not reached in either arm, with fewer than 11% of patients experiencing an event.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Acalabrutinib and its active metabolite, ACP-5862, exposures increase proportionally with dose across a dose range of 75 to 250 mg (0.75 to 2.5 times the approved recommended single dosage) in patients with B-cell malignancies. At the recommended dose of 100 mg twice daily, the geometric mean (% coefficient of variation [CV]) daily area under the plasma drug concentration over time curve (AUC<sub>24h</sub>) and maximum plasma concentration (C<sub>max</sub>) for acalabrutinib were 1843 (38%) ng&bull;h/mL and 563 (29%) ng/mL, respectively, and for ACP-5862 were 3947 (43%) ng&bull;h/mL and 451 (52%) ng/mL, respectively.</p><p dir="ltr">&nbsp;<u>Absorption</u></p><p dir="ltr">The geometric mean absolute bioavailability of acalabrutinib was 25%. Median (min, max) time to peak plasma concentration (T<sub>max</sub>) of acalabrutinib and its active metabolite, ACP-5862 were 0.5 (0.2, 3.0) hours and 0.75 (0.5, 4.0) hours, respectively.</p><p dir="ltr"><em>Effect of Food</em></p><p dir="ltr">In healthy subjects, administration of a single 100 mg dose of acalabrutinib with a high-fat, high-calorie meal (approximately 918 calories, 59 grams carbohydrate, 59 grams fat, and 39 grams protein) did not affect the mean AUC as compared to dosing under fasted conditions. Resulting C<sub>max</sub> decreased by 54% and T<sub>max</sub> was delayed 1-2 hours.</p><p dir="ltr"><u>Distribution</u></p><p dir="ltr">The geometric mean (% CV) steady-state volume of distribution (V<sub>ss</sub>) of acalabrutinib and its active metabolite, ACP-5862 was approximately 101 (52%) L and 67 (32%) L, respectively. Human plasma protein of acalabrutinib and its active metabolite, ACP-5862, were 97.5% and 98.6%, respectively. The mean blood-to-plasma ratio of acalabrutinib and its active metabolite, ACP-5862, was 0.8 and 0.7, respectively.</p><p dir="ltr"><u>Elimination</u></p><p dir="ltr">The geometric mean (% CV) terminal elimination half-life (t<sub>1/2</sub>) of acalabrutinib and its active metabolite, ACP-5862, were 1.4 (50%) hours and 6.4 (37%) hours, respectively. The geometric mean (%CV) apparent oral clearance (CL/F) of acalabrutinib and its active metabolite, ACP-5862, were 71 (35%) L/hr and 13 (42%) L/hr, respectively.</p><p dir="ltr"><em>Metabolism</em></p><p dir="ltr">Acalabrutinib is predominantly metabolized by CYP3A enzymes, and to a minor extent, by glutathione conjugation and amide hydrolysis, based on in vitro studies. ACP-5862 was identified as the major active metabolite in plasma with a geometric mean exposure (AUC) that was approximately 2- to 3-fold higher than the exposure of acalabrutinib. ACP-5862 is approximately 50% less potent than acalabrutinib with regard to BTK inhibition.</p><p dir="ltr"><em>Excretion</em></p><p dir="ltr">Following administration of a single 100 mg radiolabeled acalabrutinib dose in healthy subjects, 84% of the dose was recovered in the feces (&lt; 2% unchanged) and 12% of the dose was recovered in the urine (&lt;&nbsp;2% unchanged).</p><p dir="ltr"><u>Specific Populations</u></p><p dir="ltr">There were no clinically significant differences in the pharmacokinetics of acalabrutinib and its active metabolite, ACP-5862, based on age (32 to 90 years), sex, race (Caucasian, African American), body weight (40 to 149 kg), or mild to moderate renal impairment (eGFR &ge;&nbsp;30&nbsp;mL/min/1.73m<sup>2</sup> and eGFR &lt;&nbsp;89&nbsp;mL/min/1.73m<sup>2</sup>, as estimated by MDRD (modification of diet in renal disease equation)). The effect of severe renal impairment (eGFR &lt;&nbsp;29&nbsp;mL/min/1.73m<sup>2</sup>, MDRD) or renal impairment requiring dialysis on the pharmacokinetics of acalabrutinib is unknown.</p><p dir="ltr"><em>Patients with Hepatic Impairment</em></p><p dir="ltr">The AUC of acalabrutinib increased 1.9-fold in subjects with mild hepatic impairment (Child-Pugh class A), 1.5-fold in subjects with moderate hepatic impairment (Child-Pugh class B) and 5.3-fold in subjects with severe hepatic impairment (Child-Pugh class C) compared to subjects with normal liver function. No clinically relevant PK difference in ACP-5862 was observed in subjects with severe hepatic impairment (Child-Pugh Class C) compared to subjects with normal liver function. No clinically relevant PK differences in acalabrutinib and ACP-5862 were observed in patients with mild or moderate hepatic impairment (total bilirubin less and equal to upper limit of normal [ULN] and AST greater than ULN, or total bilirubin greater than ULN and any AST) relative to patients with normal hepatic function (total bilirubin and AST within ULN).</p><p dir="ltr"><u>Drug Interaction Studies</u></p><p dir="ltr"><em>Clinical Studies and Model-Informed Approaches</em></p><p dir="ltr"><em>Strong CYP3A Inhibitors:</em> Co-administration of acalabrutinib with itraconazole (strong CYP3A inhibitor) increase acalabrutinib C<sub>max</sub> by 3.9-fold and AUC by 5.1-fold in healthy subjects.</p><p dir="ltr"><em>Moderate CYP3A Inhibitors: </em>Co-administration of acalabrutinib with erythromycin (moderate CYP3A inhibitor), fluconazole (moderate CYP3A inhibitor), diltiazem (moderate CYP3A inhibitor) is predicted to increase acalabrutinib C<sub>max</sub> and AUC by approximately 2- to 3-fold.</p><p dir="ltr"><em>Strong CYP3A Inducers: </em>Co-administration of acalabrutinib with rifampin (strong CYP3A inducer) decreased acalabrutinib C<sub>max</sub> by 68% and AUC by 77% in healthy subjects.</p><p dir="ltr"><em>Acid-Reducing Agents:</em> No clinically significant differences in the pharmacokinetics of acalabrutinib were observed when co-administered with rabeprazole (proton pump inhibitor).</p><p dir="ltr"><em>In </em><em>V</em><em>itro Studies</em></p><p dir="ltr"><em>Cytochrome P450 (CYP) Enzymes:</em> Acalabrutinib is an inhibitor of CYP3A4/5, CYP2C8 and CYP2C9, but not CYP1A2, CYP2B6, CYP2C19, or CYP2D6. Acalabrutinib&rsquo;s active metabolite, ACP-5862, is an inhibitor of CYP2C8, CYP2C9 and CYP2C19, but not CYP1A2, CYP2B6, CYP2D6, or CYP3A4/5. Acalabrutinib is an inducer of CYP1A2, CYP2B6, and CYP3A4. Acalabrutinib&rsquo;s active metabolite, ACP-5862, is an inducer of CYP3A4.</p><p dir="ltr"><em>Uridine diphosphate (UDP)-glucuronosyl transferase (UGT) Enzymes: </em>Acalabrutinib and its active metabolite, ACP-5862, are not inhibitors of UGT1A1 or UGT2B7.</p><p dir="ltr"><em>Transporter System: </em>Acalabrutinib is an inhibitor of breast cancer resistance protein (BCRP), but not multidrug and toxin extrusion protein 1 (MATE1). Acalabrutinib&rsquo;s active metabolite, ACP-5862, is an inhibitor of MATE1, but not BCRP. Acalabrutinib and its active metabolite, ACP-5862, are not inhibitors of P-glycoprotein (P-gp), organic anion transporter (OAT) 1, OAT3, organic cation transporter 2 (OCT2), organic anion transporting polypeptide (OATP) 1B1, OATP1B3, or MATE2-K.</p><p dir="ltr">Acalabrutinib and its active metabolite, ACP-5862, are substrates of P-gp and BCRP. Acalabrutinib is not a substrate of OAT1, OAT3, OCT2, OATP1B1, or OATP1B3. Acalabrutinib&rsquo;s active metabolite, ACP-5862, is not a substrate of OATP1B1 or OATP1B3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Carcinogenicity/Genotoxicity/Mutagenicity/Phototoxicity/Fertility</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Carcinogenicity studies have not been conducted with acalabrutinib.</p><p dir="ltr">Acalabrutinib was not mutagenic in an in vitro bacterial reverse mutation (AMES) assay or clastogenic in an in vitro human lymphocyte chromosomal aberration assay or in an in vivo rat bone marrow micronucleus assay.</p><p dir="ltr">In a fertility study in rats, there were no effects of acalabrutinib on fertility in male rats at exposures 11 times, or in female rats at exposures 9 times, the AUC observed in patients at the recommended dose of 100 mg twice daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Tablet core</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Mannitol (E421)</p><p dir="ltr">Microcrystalline cellulose (E460)</p><p dir="ltr">Low-substituted hydroxypropyl cellulose (E463)</p><p dir="ltr">Sodium stearyl fumarate</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Tablet coating</u></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr">Hypromellose (E464)</p><p dir="ltr">Copovidone</p><p dir="ltr">Titanium dioxide (E171)</p><p dir="ltr">Macrogol</p><p dir="ltr">Medium-chain triglycerides</p><p dir="ltr">Iron oxide yellow (E172)</p><p dir="ltr">Iron oxide red (E172)</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 Months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">This medicinal product does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Aluminium/Aluminium blister packs with sun/moon symbols containing 8 or 10 film-coated tablets. Cartons of 56 or 60 tablets.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Not all pack sizes may be marketed.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AstraZeneca AB
SE-151 85 Södertälje
Sweden

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>